Rossari Biotech IPO: A diversified portfolio, expansion are key triggers

The expansion is expected to support growth with revenues and profits estimated to rise by 20-25 per cent over the FY20-23 period

from Latest News https://ift.tt/2PlNNtn
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share